Sei Ueda1,2,3, Mitsuro Kanda4, Yusuke Sato5, Hayato Baba1,6, Shunsuke Nakamura1, Koichi Sawaki1, Dai Shimizu1, Satoru Motoyama5, Tsutomu Fujii5, Yasuhiro Kodera1, Shuji Nomoto1,3. 1. Department of Gastroenterological Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan. 2. Department of Maxillofacial Surgery, School of Dentistry, Aichi-gakuin University Graduate School of Medicine, Nagoya, Japan. 3. Department of Surgery, School of Dentistry, Aichi-gakuin University Graduate School of Medicine, Nagoya, Japan. 4. Department of Gastroenterological Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan m-kanda@med.nagoya-u.ac.jp. 5. Department of Thoracic Surgery, Akita University Graduate School of Medicine, Akita, Japan. 6. Department of Surgery and Science, Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama, Toyama, Japan.
Abstract
BACKGROUND/AIM: To investigate the function of chromobox 2 (CBX2) in oesophageal squamous cell carcinoma (OSCC). MATERIALS AND METHODS: We used real-time quantitative reverse transcription PCR (qRT-PCR) and immunohistochemistry to determine CBX2 expression levels in 13 human OSCC cell lines and clinical specimens of two independent cohorts of patients with OSCC. RESULTS: PCR array analysis revealed that CBX2 was co-ordinately expressed with WNT5B in OSCC cell lines. RT-qPCR analysis of clinical samples revealed a high tumour-specific CBX2 expression compared with normal oesophageal tissues. High CBX2 expression was significantly associated with shorter disease-specific survival, hematogenous recurrence, and overall recurrence. Analysis of tissue microarrays of one cohort revealed that patients with higher CBX2 levels tended to have a shorter disease-specific survival. CONCLUSION: CBX2 overexpression in OSCC tissues may serve as a novel biomarker for predicting survival and hematogenous recurrence. Copyright
BACKGROUND/AIM: To investigate the function of chromobox 2 (CBX2) in oesophageal squamous cell carcinoma (OSCC). MATERIALS AND METHODS: We used real-time quantitative reverse transcription PCR (qRT-PCR) and immunohistochemistry to determine CBX2 expression levels in 13 human OSCC cell lines and clinical specimens of two independent cohorts of patients with OSCC. RESULTS: PCR array analysis revealed that CBX2 was co-ordinately expressed with WNT5B in OSCC cell lines. RT-qPCR analysis of clinical samples revealed a high tumour-specific CBX2 expression compared with normal oesophageal tissues. High CBX2 expression was significantly associated with shorter disease-specific survival, hematogenous recurrence, and overall recurrence. Analysis of tissue microarrays of one cohort revealed that patients with higher CBX2 levels tended to have a shorter disease-specific survival. CONCLUSION:CBX2 overexpression in OSCC tissues may serve as a novel biomarker for predicting survival and hematogenous recurrence. Copyright
Authors: Andrei Kuzmichev; Kenichi Nishioka; Hediye Erdjument-Bromage; Paul Tempst; Danny Reinberg Journal: Genes Dev Date: 2002-11-15 Impact factor: 11.361
Authors: Jacques Ferlay; Isabelle Soerjomataram; Rajesh Dikshit; Sultan Eser; Colin Mathers; Marise Rebelo; Donald Maxwell Parkin; David Forman; Freddie Bray Journal: Int J Cancer Date: 2014-10-09 Impact factor: 7.396
Authors: Nathaniel Rothman; Montserrat Garcia-Closas; Nilanjan Chatterjee; Nuria Malats; Xifeng Wu; Jonine D Figueroa; Francisco X Real; David Van Den Berg; Giuseppe Matullo; Dalsu Baris; Michael Thun; Lambertus A Kiemeney; Paolo Vineis; Immaculata De Vivo; Demetrius Albanes; Mark P Purdue; Thorunn Rafnar; Michelle A T Hildebrandt; Anne E Kiltie; Olivier Cussenot; Klaus Golka; Rajiv Kumar; Jack A Taylor; Jose I Mayordomo; Kevin B Jacobs; Manolis Kogevinas; Amy Hutchinson; Zhaoming Wang; Yi-Ping Fu; Ludmila Prokunina-Olsson; Laurie Burdett; Meredith Yeager; William Wheeler; Adonina Tardón; Consol Serra; Alfredo Carrato; Reina García-Closas; Josep Lloreta; Alison Johnson; Molly Schwenn; Margaret R Karagas; Alan Schned; Gerald Andriole; Robert Grubb; Amanda Black; Eric J Jacobs; W Ryan Diver; Susan M Gapstur; Stephanie J Weinstein; Jarmo Virtamo; Victoria K Cortessis; Manuela Gago-Dominguez; Malcolm C Pike; Mariana C Stern; Jian-Min Yuan; David J Hunter; Monica McGrath; Colin P Dinney; Bogdan Czerniak; Meng Chen; Hushan Yang; Sita H Vermeulen; Katja K Aben; J Alfred Witjes; Remco R Makkinje; Patrick Sulem; Soren Besenbacher; Kari Stefansson; Elio Riboli; Paul Brennan; Salvatore Panico; Carmen Navarro; Naomi E Allen; H Bas Bueno-de-Mesquita; Dimitrios Trichopoulos; Neil Caporaso; Maria Teresa Landi; Federico Canzian; Borje Ljungberg; Anne Tjonneland; Francoise Clavel-Chapelon; David T Bishop; Mark T W Teo; Margaret A Knowles; Simonetta Guarrera; Silvia Polidoro; Fulvio Ricceri; Carlotta Sacerdote; Alessandra Allione; Geraldine Cancel-Tassin; Silvia Selinski; Jan G Hengstler; Holger Dietrich; Tony Fletcher; Peter Rudnai; Eugen Gurzau; Kvetoslava Koppova; Sophia C E Bolick; Ashley Godfrey; Zongli Xu; José I Sanz-Velez; María D García-Prats; Manuel Sanchez; Gabriel Valdivia; Stefano Porru; Simone Benhamou; Robert N Hoover; Joseph F Fraumeni; Debra T Silverman; Stephen J Chanock Journal: Nat Genet Date: 2010-10-24 Impact factor: 38.330
Authors: Toshima Z Parris; Luaay Aziz; Anikó Kovács; Shahin Hajizadeh; Szilárd Nemes; May Semaan; Chang Yan Chen; Per Karlsson; Khalil Helou Journal: BMC Cancer Date: 2014-05-07 Impact factor: 4.430